Sepsis is one of the leading causes of mortality worldwide. 20 to 30 million cases of sepsis are registered annually in the world, with 50 people being killed every hour.
Annually, it affects 50,000 people in Spain, of whom 17,000 die. In the last ten years, cases of sepsis have doubled and studies believe that the trend will continue to be high.
Recent studies on sepsis and infection in vivo have seen a great increase of microvesicles (MV) in blood and have studied the utility of said MV for the differentiation between other pathologies of bacterial origin. MVs play an important role in the defense against pathogens that are therefore beneficial as part of the natural response to infection.
The present invention, therefore, refers, as a first aspect, to the use of endothelial microvesicles (MVe) to make a new medicament (preferably an antibiotic), since they possess a potent antimicrobial capacity both on the main pathogens involved in sepsis as well as on multiresistant bacterias to the conventional antibiotics. These MVs cause the destruction of bacteria but do not affect eukaryotic cells. Alternatively, the present invention also relates to MV derived from endothelial cells for its use as a medicament.
This new function discovered about the MV is of great diagnostic utility and also offers a wide variety of therapeutic targets, as well as an alternative to antibiotics for the treatment of infectious pathologies such as sepsis. That bactericidal action of the MVe of the invention is carried out even at physiological concentrations, and with a high concentration of microorganisms, specifically bacteria, being this action stronger when higher is the concentration of MVe.
The group seeks to reach licensing agreements, cooperation or commercial agreements with technical assistance, with pharmaceutical companies and R&D institutions interested in the design of new medicines.